IBRX ImmunityBio, Inc. stock chart & analysis

Conviction 40HealthcareScan · Fri, Nov 6, 2026

Bullish harami

ImmunityBio, Inc. (IBRX) closed at $8.64 (+7.80%) on Nov 6, 2026. Its latest daily candle is a bullish harami. Price is below its 50-day and above its 200-day moving average. RSI(14) 49, RS Rating 99, -30.6% from its 52-week high, +335.9% year to date. Sector: Healthcare · Biological Products, (No Diagnostic Substances).

IBRX$8.64+7.80%

ResistanceSupportVol 14Insider sellCongress buyCongress sell

Loading chart…

ImmunityBio, Inc.Biological Products, (No Diagnostic Substances)www.immunitybio.com ↗

Price8.64

Change+7.80%

Gap+1.69%

Rel volume0.47×

Avg volume12.34M

Avg $ vol110.31M

SMA 208.77

SMA 508.74

SMA 2007.96

Price vs 50-1.24%

Price vs 200+8.42%

MA stackmixed

50/200 cross—

Supertrenddown · 10.08

RSI (14)49

MACD hist-0.04

MACD cross—

Stoch %K / %D71 / 45

ADX (14)17

+DI / −DI19 / 21

RSI divergence—

MACD divergence—

ATR %7.82%

ADR %7.91%

52w high12.43

52w low1.95

From 52w high-30.57%

Above 52w low+342.56%

New 52w highNo

SqueezeOff

Bollinger width30.95%

%B0.45

Donchian pos30.66%

Donchian high10.62

Donchian low7.75

AVWAP (52w high)8.30

vs AVWAP high+3.93%

AVWAP (52w low)7.14

vs AVWAP low+20.86%

OBV trendDown

Chaikin MF (20)-0.18

Today vs 20d0.47×

Avg vol (14d)9.49M

Avg vol (20d)12.34M

Avg $ vol (20d)110.31M

Market cap9.15B

RS Rating99 / 99

RS 3m (vs SPY)+20.09%

RS 6m (vs SPY)+1.71%

RS line new highNo

Trend template6/8

Technical rank69.7

1 week+4.10%

1 month-12.92%

3 months+15.22%

6 months+1.41%

1 year+301.40%

YTD+335.86%

P/E-26.03

P/B-8.74

P/S80.74

P/FCF-29.62

EPS-0.3800

Div yield—

ROE33.57%

ROA-55.91%

Debt/Eq-0.00

Current5.72

EV/EBITDA-37.72

Gross margin99.34%

Net margin-310.18%

Rev growth668.31%

EPS growth15.03%

Price target14.25

Target upside65.12%

Analyst ratingBuy

Institutional22.49%

Ent. value9.07B

Revenue51.24M

Net income-230.38M

Gross profit50.94M

Free cash flow-308.78M

IndustryBiological Products, (No Diagnostic Substances)

ExchangeNasdaq

Shares out1.05B

Employees691

ListedWed, Mar 10, 2021

Free float368.17M

Float %35.8%

Short interest—

Days to cover—

Short volume63.3%

Squeeze score—

Next earnings—

EPS forecast—

Last EPS vs est−$0.08 vs −$0.09

Last surprise+11.1% beat

Setup gradeD

Conviction40 / 100

Pattern quality—

Tech rank69.7 / 100

Group rank23 / 100

Status lane—

Setup direction—

Pattern family

Resistance—

Support—

Days since event—

Candle confirmBullish harami

Financials as of Tue, Jun 30, 2026 · quarterly.

IBRX technical analysis

Trend

IBRX's moving averages are mixed — no clean uptrend or downtrend. It closed 1.2% below the 50-day ($8.74) and 8.4% above the 200-day ($7.96). ADX(14) at 17 points to a weak trend — more range than direction. It meets 6 of 8 trend-template criteria.

Momentum

RSI(14) is 49, in the bearish half of its range. The MACD histogram is negative. Its RS Rating of 99 puts its weighted 12-month performance ahead of about 99% of the US market.

Volume and volatility

Volume on the latest session ran 0.5× its 20-day average. It trades about $110.3M a day on average. ATR(14) is $0.6750, 7.8% of price — its typical daily range. On-balance volume is trending down. Chaikin Money Flow (-0.18) shows distribution.

Key levels

The 52-week range is $1.95 to $12.43; price is 30.6% below the high and 342.6% above the low. The VWAP anchored at the 52-week high is $8.30, below price.

Performance

IBRX returned +4.1% (1 week), -12.9% (1 month), +15.2% (3 months), +1.4% (6 months), +301.4% (1 year), +335.9% (year to date).

About ImmunityBio, Inc.

ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.

Biological Products, (No Diagnostic Substances) · Listed 2021 · 691 employees

Congress activity

Disclosed STOCK Act trades in IBRX · 2 recent

All disclosures →

Member	Side	Amount	Traded	Filed	PTR
Lisa McClain house · R · MI · traded 2026-09-30	Buy	$1K–$15K	2026-09-30	2026-10-12	PDF
Lisa McClain house · R · MI · traded 2026-09-28	Buy	$1K–$15K	2026-09-28	2026-10-12	PDF

Insider activity

SEC Form 4 transactions in IBRX · open-market 1 sell

Insider	Side	Shares	Value	Traded	Filed
Wendel Bruce Director · Stock Option (right to buy) · 2026-06-09	Grant	65.6K	$0	2026-06-09	2026-06-10
BLASZYK MICHAEL D Director · Stock Option (right to buy) · 2026-06-09	Grant	65.6K	$0	2026-06-09	2026-06-10
Cohen Cheryl Director · Stock Option (right to buy) · 2026-06-09	Grant	65.6K	$0	2026-06-09	2026-06-10
Clark Wesley Director · Stock Option (right to buy) · 2026-06-09	Grant	65.6K	$0	2026-06-09	2026-06-10
Selecky Christobel Director · Stock Option (right to buy) · 2026-06-09	Grant	65.6K	$0	2026-06-09	2026-06-10
MAXWELL LINDA Director · Stock Option (right to buy) · 2026-06-09	Grant	65.6K	$0	2026-06-09	2026-06-10
Simon Barry J. Director · Common Stock · 2026-06-04	Sell	23.03K	$165K	2026-06-04	2026-06-05

SEC filings

EDGAR filings in IBRX · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.

Start free — 7-day trial, no card →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.